How the Coinbase Founder’s $3.1B Longevity Biotech NewLimit Chose the Most Boring Path in Medicine.What That Means for Peptide & Wellness Bros Dragging Cutting-Edge Longevity Into Reimbursed Health

Thoughts on Healthcare Markets & Technology Podcast

0:00

-7:37

Paid episode

The full episode is only available to paid subscribers of Thoughts on Healthcare Markets & Technology

How the Coinbase Founder’s $3.1B Longevity Biotech NewLimit Chose the Most Boring Path in Medicine.What That Means for Peptide & Wellness Bros Dragging Cutting-Edge Longevity Into Reimbursed Health

Jun 09, 2026

∙ Paid

Brian Armstrong disrupted finance by attacking slow legacy systems. Then he built a longevity company that does everything the slow legacy way. That tension turns out to be the most important strategic signal in biotech right now.

NewLimit just closed a $435M Series C at a $3.1B valuation. First human trial in 2027. Target: alcohol-induced liver disease.…

Continue reading this post for free, courtesy of Thoughts on Healthcare.

Or purchase a paid subscription.